Drug Profile
Cerliponase alfa - BioMarin Pharmaceutical
Alternative Names: BMN 190; BRINEURA; Brineura; recombinant human tripeptidyl peptidase-1; rhTPP1Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator BioMarin Pharmaceutical
- Class Enzymes; Peptide hydrolases; Recombinant proteins
- Mechanism of Action Tripeptidyl peptidase 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuronal ceroid lipofuscinosis
Most Recent Events
- 20 Apr 2022 BioMarin Pharmaceutical completes a phase II trial in Neuronal ceroid lipofuscinosis (In adolescents, In children) in USA, Germany, Italy and United Kingdom (Intracerebroventricular) (NCT02678689) (EudraCT2015-000891-85)
- 31 Dec 2020 BioMarin Pharmaceutical has patent protection for Cerliponase alpha in USA and European union
- 10 Dec 2020 BioMarin Pharmaceutical completed a phase-II trials in Neuronal ceroid lipofuscinosis (In children, In adolescents) in Germany, Italy, USA and United Kingdom (Intracerebral) (NCT02485899)